Dermatology
Case Report
Marginal Papular Acrokeratodermas: No Racial Limitations for a Clinical Spectrum That Responds to AcitretinLambiris A.G.a · Newman P.L.bDepartments of aDermatology and bHistopathology, Derriford Hospital, Plymouth, UK
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: September 03, 2001
Issue release date: 2001
Number of Print Pages: 3
Number of Figures: 3
Number of Tables: 0
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Abstract
Marginal papular acrokeratoderma (MPA) encompasses a group of disorders that share crateriform, keratotic papules along the margins of the hands and feet. We report a unique case of a Philippino woman, with focal acral hyperkeratosis (FAH) associated with sensorineural hearing loss. The clinical phenotype of FAH (hereditary MPA without elastorrhexis) is expanded and the hypothesis of a racially limited disorder is weakened. Effective treatment of this embarrassing condition with acitretin is demonstrated.
© 2001 S. Karger AG, Basel
Related Articles:
References
-
Griffiths WAD, Judge MR, Leigh IM: Disorders of keratinization; in Champion RH, Burton JL, Burns DA, Breathnach SM (eds): Textbook of Dermatology. Oxford, Blackwell Sciences, 1998, vol 2, pp 1557–1559.
- Dowd PM, Harman RRM, Black MM: Focal acral hyperkeratosis. Br J Dermatol 1983;109:97–103.
- Rongioletti F, Betti R, Crosti C, Rebora A: Marginal papular acrokeratodermas: A unified nosography for focal acral hyperkeratosis, acrokeratoelastoidosis and related disorders. Dermatology 1994;188:28–31.
- Fitzgerald DA, Verbov JL: Hereditary palmoplantar keratoderma with deafness. Br J Dermatol 1996;134:939–942.
- Sharland M, Bleach NR, Goberdhan PD, Pattou MA: Autosomal dominant palmoplantar hyperkeratosis and sensorineural deafness in three generations. J Med Genet 1992;29:50–52.
- Abulafia J, Vignale RA: Degenerative collagenous plaques of the hands and acrokeratoelastoidosis: Pathogenesis and relationship with knuckle pads. Int J Dermatol 2000;39:424–432.
-
Costa OG: Acrokeratoelastoidosis. Dermatologica 1953;107:164.
- Boudghene-Stambouli O, Merad-Boudia A, Khedim A: Acrokérato-élastoïdose de Costa. Ann Dermatol Vénéréol 1993;120:539.
- Fiallo P, Pesce C, Brusasco A, Nunzi E: Acrokeratoelastoidosis of Costa: A primary disease of the elastic tissue? J Cutan Pathol 1998;25:580–582.
- Sevior KB, Hatamochi A, Stewart IA, Bykhovskaya Y, Allen-Powell DR, Fischel-Ghodsian N, Maw MA: Mitochondrial A7445G mutation in two pedigrees with palmoplantar keratoderma and deafness. Am J Med Genet 1998;75:179–185.
- Handfield-Jones S, Kennedy CTC: Acrokeratoelastoidosis treated with etretinate. J Am Acad Dermatol 1987;17:881–882.
Article / Publication Details
Published online: September 03, 2001
Issue release date: 2001
Number of Print Pages: 3
Number of Figures: 3
Number of Tables: 0
ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)
For additional information: https://www.karger.com/DRM
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
